Last reviewed · How we verify
Low-intensity chemotherapy regimen
Low-intensity chemotherapy regimens use reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing toxicity in vulnerable patient populations.
Low-intensity chemotherapy regimens use reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing toxicity in vulnerable patient populations. Used for Hematologic malignancies in elderly or frail patients, Acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy.
At a glance
| Generic name | Low-intensity chemotherapy regimen |
|---|---|
| Sponsor | Amgen |
| Drug class | Chemotherapy regimen (multi-agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Low-intensity chemotherapy (also called reduced-intensity or metronomic chemotherapy) delivers chemotherapeutic drugs at lower doses, either continuously or at frequent intervals, rather than in high-dose pulses. This approach aims to maintain anti-tumor efficacy while reducing severe adverse effects, making it suitable for elderly patients, those with comorbidities, or those unable to tolerate standard-dose regimens. The mechanism relies on direct cytotoxicity against cancer cells and may also involve anti-angiogenic effects through continuous low-dose exposure.
Approved indications
- Hematologic malignancies in elderly or frail patients
- Acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy
Common side effects
- Myelosuppression (anemia, thrombocytopenia, neutropenia)
- Nausea and vomiting
- Mucositis
- Infection
- Fatigue
Key clinical trials
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer (NA)
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC (PHASE3)
- Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (PHASE1, PHASE2)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-intensity chemotherapy regimen CI brief — competitive landscape report
- Low-intensity chemotherapy regimen updates RSS · CI watch RSS
- Amgen portfolio CI